BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Menon RM, Klein CE, Podsadecki TJ, Chiu YL, Dutta S, Awni WM. Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers. Br J Clin Pharmacol 2016;81:929-40. [PMID: 26710243 DOI: 10.1111/bcp.12873] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Ogbuagu O, Friedland G, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opinion on Drug Metabolism & Toxicology 2016;12:721-31. [DOI: 10.1080/17425255.2016.1183644] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
2 Ocque AJ, Hagler CE, DiFrancesco R, Morse GD, Talal AH. Ultra-performance liquid chromatography tandem mass spectrometry for determination of Direct Acting Antiviral drugs in human liver fine needle aspirates. J Chromatogr B Analyt Technol Biomed Life Sci 2017;1052:103-9. [PMID: 28365413 DOI: 10.1016/j.jchromb.2017.03.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
3 Ocque AJ, Hagler CE, Difrancesco R, Woolwine-Cunningham Y, Bednasz CJ, Morse GD, Talal AH. Development and validation of a UPLC-MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver. Bioanalysis 2016;8:1353-63. [PMID: 27277877 DOI: 10.4155/bio-2016-0040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
4 Lin CW, Dutta S, Zhao W, Asatryan A, Campbell A, Liu W. Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers. Eur J Drug Metab Pharmacokinet 2018;43:81-90. [PMID: 28688001 DOI: 10.1007/s13318-017-0428-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
5 Feng HP, Caro L, Fandozzi C, Chu X, Guo Z, Talaty J, Panebianco D, Dunnington K, Du L, Hanley WD, Fraser IP, Mitselos A, Denef JF, De Lepeleire I, de Hoon JN, Vandermeulen C, Marshall WL, Jumes P, Huang X, Martinho M, Valesky R, Butterton JR, Iwamoto M, Yeh WW. Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers. Antimicrob Agents Chemother 2019;63:e02142-18. [PMID: 30745392 DOI: 10.1128/AAC.02142-18] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Lin CW, Dutta S, Asatryan A, Chiu YL, Wang H, Clifton J 2nd, Campbell A, Liu W. Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of ABT-493: A First-In-Human Study. J Pharm Sci 2017;106:645-51. [PMID: 27863806 DOI: 10.1016/j.xphs.2016.10.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
7 Polepally AR, Mensing S, Khatri A, Beck D, Liu W, Awni WM, Menon RM, Dutta S. Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies. Clin Pharmacokinet 2016;55:1091-101. [PMID: 27000758 DOI: 10.1007/s40262-016-0385-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
8 Flisiak R, Flisiak-Jackiewicz M. Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C. Expert Rev Gastroenterol Hepatol 2017;11:559-67. [PMID: 28317409 DOI: 10.1080/17474124.2017.1309284] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
9 Hasan M, Parvez MSA, Azim KF, Imran MAS, Raihan T, Gulshan A, Muhit S, Akhand RN, Ahmed SSU, Uddin MB. Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: A drug repurposing and molecular docking approach. Biomed Pharmacother 2021;140:111742. [PMID: 34052565 DOI: 10.1016/j.biopha.2021.111742] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Menon RM, Klein CE, Podsadecki TJ, Chiu YL, Dutta S, Awni WM. Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers. Br J Clin Pharmacol 2016;81:929-40. [PMID: 26710243 DOI: 10.1111/bcp.12873] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
11 González-Colominas E, Londoño MC, Morillas RM, Torras X, Mojal S, Lens S, López D, Gallego A, Mariño Z, Ardèvol M, Pagès N, Solà R, Carrión JA. Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir ± DASABUVIR ± ribavirin in clinical practice. J Gastroenterol Hepatol 2018;33:1100-7. [PMID: 28994141 DOI: 10.1111/jgh.14014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Okubo H, Ando H, Sorin Y, Nakadera E, Fukada H, Morishige J, Miyazaki A, Ikejima K. Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C. PLoS One 2018;13:e0196747. [PMID: 29709031 DOI: 10.1371/journal.pone.0196747] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
13 Polepally AR, King JR, Ding B, Shuster DL, Dumas EO, Khatri A, Chiu YL, Podsadecki TJ, Menon RM. Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers. Clin Pharmacokinet 2016;55:1003-14. [PMID: 26895022 DOI: 10.1007/s40262-016-0373-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
14 Lin CW, Menon R, Liu W, Podsadecki T, Shulman N, DaSilva-Tillmann B, Awni W, Dutta S. Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies. Clin Drug Investig 2017;37:647-57. [PMID: 28378135 DOI: 10.1007/s40261-017-0520-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Menon RM, Polepally AR, Khatri A, Awni WM, Dutta S. Clinical Pharmacokinetics of Paritaprevir. Clin Pharmacokinet 2017;56:1125-37. [PMID: 28236252 DOI: 10.1007/s40262-017-0520-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
16 San SN, Matsumoto J, Saito Y, Koike M, Sakaue H, Kato Y, Fujiyoshi M, Ariyoshi N, Yamada H. Minor contribution of CYP3A5 to the metabolism of hepatitis C protease inhibitor paritaprevir in vitro. Xenobiotica 2019;49:935-44. [PMID: 30227770 DOI: 10.1080/00498254.2018.1524947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Shen J, Serby M, Reed A, Lee AJ, Zhang X, Marsh K, Khatri A, Menon R, Kavetskaia O, Fischer V. Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans. Drug Metab Dispos 2016;44:1164-73. [PMID: 27179127 DOI: 10.1124/dmd.115.067488] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
18 Mensing S, Eckert D, Sharma S, Polepally AR, Khatri A, Podsadecki TJ, Awni WM, Menon RM, Dutta S. Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials. Br J Clin Pharmacol 2017;83:527-39. [PMID: 27662429 DOI: 10.1111/bcp.13138] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
19 Zha J, Ding B, Wang H, Zhao W, Yu C, Alves K, Mobashery N, Luo Y, Menon RM. Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients. Eur J Drug Metab Pharmacokinet 2019;44:43-52. [PMID: 29909549 DOI: 10.1007/s13318-018-0492-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Venuto CS, Markatou M, Woolwine-Cunningham Y, Furlage R, Ocque AJ, DiFrancesco R, Dumas EO, Wallace PK, Morse GD, Talal AH. Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques. Antimicrob Agents Chemother 2017;61:e02283-16. [PMID: 28264852 DOI: 10.1128/AAC.02283-16] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
21 Farouk F, Wahba D, Mogawer S, Elkholy S, Elmeligui A, Abdelghani R, Ibahim S. Development and Validation of a New LC-MS/MS Analytical Method for Direct-Acting Antivirals and Its Application in End-Stage Renal Disease Patients. Eur J Drug Metab Pharmacokinet 2020;45:89-99. [PMID: 31667795 DOI: 10.1007/s13318-019-00584-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]